TP53 and Miyoshi myopathy: In 5 of the 15 MM patients with CR after chemotherapy, 18F-FDG uptake in lesions was still not reduced to normal levels, and in 4 of these 5 patients it was reduced to normal half a year after ASCT; the remaining patient had IgD-κ MM and a p53 gene mutation detected at the onset of disease and this patient was therefore given thalidomide and interferon for maintenance therapy after transplantation, and 18F-FDG uptake was reduced to normal one year after ASCT.